New hope for tough lymphoma: glofitamab study launches in china
NCT ID NCT07200375
First seen Nov 01, 2025 · Last updated Jun 13, 2026 · Updated 30 times
Summary
This study looks at how well and how safe a drug called glofitamab works for Chinese adults whose large B-cell lymphoma has come back or not responded to one prior treatment. About 300 participants will receive glofitamab-based therapy and be followed to see how long they live without the cancer getting worse. The goal is to find a better second-line option for this hard-to-treat cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences.
RECRUITINGLangfang, Hebei, 065001, China
-
Chinese Academy of Medical Sciences Hematology Hospital;Lymphoma Diagnosis and Treatment Center
RECRUITINGTianjin, Tianjin Municipality, 301636, China
-
Guangdong Provincial People's Hospital
RECRUITINGGuangzhou, 510080, China
-
Harbin Medical University Cancer Hospital
RECRUITINGHarbin, 150081, China
-
Henan Cancer Hospital
RECRUITINGZhengzhou, 450008, China
-
Peking University People's Hospital
RECRUITINGBeijing, 100044, China
-
Peking University Third Hospital
RECRUITINGBeijing, 100191, China
-
Queen Mary Hospital
RECRUITINGHong Kong, Hong Kong
-
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
RECRUITINGShanghai, 200025, China
-
Shandong Cancer Hospital
RECRUITINGJinan, 250117, China
-
The First Affiliated Hospital of Wenzhou Medical University
RECRUITINGWenzhou, 325035, China
-
The First Affiliated Hospital of Xian Jiao Tong University
RECRUITINGXi'an, 710061, China
-
The First Bethune Hospital of Jilin University
RECRUITINGChangchun, China
-
Tianjin Cancer Hospital
RECRUITINGTianjin, 300060, China
-
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology
RECRUITINGWuhan, 430030, China
-
West China Hospital of Sichuan University
RECRUITINGChengdu, 610041, China
-
Xiehe Hospital, Tongji Medical College Huazhong University of Science & Technology
RECRUITINGWuhan, 430022, China
-
Yantai Yu Huangding Hospital
RECRUITINGYantai, 264099, China
Conditions
Explore the condition pages connected to this study.